Vertex cystic fibrosis triple combo therapy succeeds in important trials

The trials tested the experimental drug VX-445 in combination with Vertex's backbone double-drug combination. Its current products can benefit roughly 50 percent of CF patients, and the highly-anticipated positive data would represent a major expansion of the treatable population. The company had previously tested another experimental drug, VX-659, with the two-drug combination approved under the brand name Symdeko.